← Back to patent-cliff list
CAS 1459721-13-1
(R)-perfluorophenyl quinuclidin-3-yl carbonate
Codes: SOLIF-016
Application context (from source-drug indications)
Lower urinary tract symptomsSolifenacin Succinate/Tamsulosin HydrochlorideBenign prostatic hyperplasiaSolifenacin Succinate/Tamsulosin HydrochlorideOveractive bladderSolifenacin Succinate/Tamsulosin HydrochlorideDrug-related adverse effects and reactionsSolifenacin Succinate/Tamsulosin HydrochlorideBladder neck obstructionSolifenacin Succinate/Tamsulosin HydrochlorideOveractive bladderSolifenacin SuccinateUrge incontinenceSolifenacin SuccinateUrinary tract diseaseSolifenacin Succinate
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Solifenacin Succinate/Tamsulosin Hydrochloride | Tier C — Watch / trade | - |
| Solifenacin Succinate | Tier B — Position early | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline→(R)-quinuclidin-3-ol→succinic acid→perfluorophenyl (2,3,4,5-tetrafluorophenyl) carbonate→(R)-perfluorophenyl quinuclidin-3-yl carbonate
(S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline→(R)-quinuclidin-3-ol→succinic acid→perfluorophenyl (2,3,4,5-tetrafluorophenyl) carbonate→(R)-perfluorophenyl quinuclidin-3-yl carbonate
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.